Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations-MedSci.cn

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations

Johnson, ML; Steuer, CE; Hayashi, H; Su, WC; Nishio, M; Kim, DW; Koczywas, M; Felip, E; Gold, KA; Murakami, H; Baik, CS; Kim, SW; Smit, EF; Gigantone, M; Kim, B; Fan, PD; Qi, Z; Wu, EY; Sternberg, D; Jänne, PA

JOURNAL OF THORACIC ONCOLOGY, 2023; 18 (3): E30

科室
- - 订阅+
  - 更多科室
工具
服务